Provided by Tiger Trade Technology Pte. Ltd.

Roivant Sciences Ltd.

25.82
+4.6822.14%
Post-market: 25.37-0.4500-1.74%19:59 EST
Volume:24.05M
Turnover:604.18M
Market Cap:18.48B
PE:-48.18
High:25.95
Open:24.48
Low:23.97
Close:21.14
52wk High:25.95
52wk Low:8.73
Shares:715.70M
Float Shares:467.00M
Volume Ratio:4.40
T/O Rate:5.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5359
EPS(LYR):-0.2371
ROE:-17.36%
ROA:-12.43%
PB:4.24
PE(LYR):-108.91

Loading ...

Roivant Sciences (ROIV) Is Up 19.4% After Advancing Phase 2 Pipeline Despite Wider Quarterly Loss

Simply Wall St.
·
Yesterday

Analysts Are Bullish on These Healthcare Stocks: Knight Therapeutics (KHTRF), Roivant Sciences (ROIV)

TIPRANKS
·
Yesterday

BUZZ-U.S. STOCKS ON THE MOVE-SpyGlass, Agomab, Piper Sandler, Molina

Reuters
·
Yesterday

Roivant Sciences Up Over 17%, on Track for Record High Close -- Data Talk

Dow Jones
·
Yesterday

BUZZ-U.S. STOCKS ON THE MOVE-Microchip, Under Armour, Avery Dennison

Reuters
·
Feb 06

Roivant Sciences rises 16.9%

TIPRANKS
·
Feb 06

Stock Track | Roivant Sciences Soars 19.68% Intraday on Positive Phase 2 Results for Skin Disease Drug

Stock Track
·
Feb 06

Roivant Shares Rise on Positive Skin Disease Treatment Results

Dow Jones
·
Feb 06

Wall Street Set to Open Modestly Higher Friday as Tech Stocks Stabilize Following Week-Long Rout

MT Newswires Live
·
Feb 06

BRIEF-Priovant Announces Positive Phase 2 Results For Brepocitinib In Cutaneous Sarcoidosis (Cs)

Reuters
·
Feb 06

Priovant's Brepocitinib Shows Skin Disease Improvement in Phase 2 Study; Pulmovant Completes Lung Disease Trial Enrollment

MT Newswires Live
·
Feb 06

Shares of Roivant up 15.8% Premarket After Experimental Drug Shows Benefit in Rare Skin Disease, Q3 Results

THOMSON REUTERS
·
Feb 06

Roivant Sciences posts nine-month revenue of USD 5.74 million, down 73 percent

Reuters
·
Feb 06

S&P 500 Futures Climb In Premarket Trading; Doximity, Stellantis Lag

Dow Jones
·
Feb 06

BUZZ-Roivant shares rise as experimental drug shows benefit in rare skin disease

Reuters
·
Feb 06

Roivant swings to Q3 loss as revenue drops

Reuters
·
Feb 06

Earnings Flash (ROIV) Roivant Sciences Posts Fiscal Q3 Net Loss $0.38 a Share, vs. FactSet Est of $0.30 Loss

MT Newswires Live
·
Feb 06

Stock Track | Roivant Sciences Soars 9.93% in Pre-market on Positive Phase 2 Results for Brepocitinib

Stock Track
·
Feb 06

Immunovant Q3 net loss smaller than expected

Reuters
·
Feb 06

Roivant Sciences Q3 Adj. EPS $(0.24) Beats $(0.32) Estimate, Sales $1.999M

Benzinga
·
Feb 06